Gilead Sciences names new senior vice president of development operations

In this role, Dr Cheng will be responsible for Gilead’s biometrics, clinical operations, drug safety and public health, project and portfolio management, and regulatory affairs activities, reporting to Norbert Bischofberger, executive vice president of R&D and chief scientific officer. With his promotion, Dr Cheng will join Gilead’s executive committee.

Dr Cheng joined Gilead in 1999 and most recently served as vice president of clinical research, overseeing clinical development activities for the company’s development-stage programs in HIV/AIDS. Prior to joining Gilead, Dr Cheng trained in internal medicine at the University of California, Los Angeles.

Dr Bischofberger said: “Over the past decade, Andrew has played a key leadership role overseeing multiple clinical programs, including pivotal studies supporting the approval of our HIV medications and clinical program design for our investigational HIV candidate, elvitegravir, and our novel pharmacoenhancer, GS 9350.

“With a growing number of programs currently in our R&D pipeline and the increasing complexity of our business, Andrew’s new role will help us maintain an efficient and cost-effective approach to development, enhancing collaboration across our four therapeutic areas and ensuring we can advance promising candidates as quickly as possible.”